In a 2023 framework, the World Health Organization (WHO) defined meaningful engagement as the respectful, dignified, and equitable inclusion of individuals with lived experience, following
With over 30 million individuals in the United States alone affected by 7,000 rare diseases,1 it is crucial to provide these patients with timely access to diagnosis and prompt t
Donovan Quill, AscellaHealth’s Executive Vice President of Growth and Strategy, describes the unique challenges associated with bringing new specialty and rare disease pharmaceutical produc
Industry stakeholders have moved beyond considering patients as clinical trial “subjects”, and instead recognise the tremendous value of viewing those most impacted by a disease as partners